Although breast cancer treatment has made great progress, the threat of recurrence of breast cancer after surgery has always been in the mind of every breast cancer patient. To understand the risk of recurrence after surgery, oncogene testing has been carried out in Europe and America to guide postoperative treatment, reduce the harm caused by unnecessary chemotherapy and provide targeted treatment drugs. At present, the 21-gene test technology for breast cancer has also been carried out in China, through the results of the genetic test to make recurrence risk score, and according to the determination of 6 drug-sensitive genes, to select tumor-sensitive drugs, reduce harmful and ineffective chemotherapy, improve the targeted treatment plan, reduce over-treatment and under-treatment, so that patients can achieve truly individualized treatment, rather than a one-size-fits-all chemotherapy plan.